- Home
- BOLT vs ACXP Comparison
BOLT vs ACXP Comparison
Compare BOLT & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- ACXP
- Stock Information
- Founded
- BOLT 2015
- ACXP 2017
- Country
- BOLT United States
- ACXP United States
- Employees
- BOLT N/A
- ACXP N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- ACXP Health Care
- Exchange
- BOLT Nasdaq
- ACXP Nasdaq
- Market Cap
- BOLT 9.4M
- ACXP 9.1M
- IPO Year
- BOLT 2021
- ACXP 2021
- Fundamental
- Price
- BOLT $5.19
- ACXP $4.09
- Analyst Decision
- BOLT Buy
- ACXP Strong Buy
- Analyst Count
- BOLT 3
- ACXP 3
- Target Price
- BOLT $47.50
- ACXP $143.67
- AVG Volume (30 Days)
- BOLT 14.4K
- ACXP 85.5K
- Earning Date
- BOLT 08-14-2025
- ACXP 08-12-2025
- Dividend Yield
- BOLT N/A
- ACXP N/A
- EPS Growth
- BOLT N/A
- ACXP N/A
- EPS
- BOLT N/A
- ACXP N/A
- Revenue
- BOLT $4,167,000.00
- ACXP N/A
- Revenue This Year
- BOLT N/A
- ACXP N/A
- Revenue Next Year
- BOLT N/A
- ACXP N/A
- P/E Ratio
- BOLT N/A
- ACXP N/A
- Revenue Growth
- BOLT N/A
- ACXP N/A
- 52 Week Low
- BOLT $4.59
- ACXP $3.80
- 52 Week High
- BOLT $14.36
- ACXP $44.00
- Technical
- Relative Strength Index (RSI)
- BOLT 46.64
- ACXP 33.75
- Support Level
- BOLT $4.81
- ACXP $3.83
- Resistance Level
- BOLT $5.28
- ACXP $7.15
- Average True Range (ATR)
- BOLT 0.26
- ACXP 0.60
- MACD
- BOLT 0.01
- ACXP 0.05
- Stochastic Oscillator
- BOLT 70.26
- ACXP 7.83
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.